- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)
This study is looking at two medicines, venetoclax and azacitidine, to see if they can help people with a type of blood cancer called acute myeloid leukemia (AML) stay well after their first round of treatment. It's a key stage of research to check their safety and how well they work.
For: Acute Myeloid Leukemia in First RemissionGermany · Greece · Czechia - Ongoing, recruitingPhase II and Phase III (Integrated)
ORACLE - Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T cell Lymphoma
This study is for people with a type of blood cancer called angioimmunoblastic T-cell lymphoma that has come back or not responded to previous treatment. It's testing a new oral medicine (a tablet) called azacitidine against standard treatments to see if it can stop the cancer from getting worse.
For: Relapsed or Refractory Angioimmunoblastic T cell LymphomaFrance - RecruitingPHASE1, PHASE2
A Study of BGB-11417 in Participants With Myeloid Malignancies
This study is looking at a new drug, BGB-11417, for certain blood cancers like acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Researchers want to see if it's safe, what dose works best, and if it helps people, either alone or with another treatment called azacitidine.
For: Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative NeoplasmUnited States · Australia · China - Active not recruitingPHASE3
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
This study looks at a new drug (AG-120) combined with a standard treatment (azacitidine) for adults newly diagnosed with a specific type of acute myeloid leukaemia (AML) that has a particular gene change (IDH1 mutation). It compares this combination to azacitidine alone to see if it works better.
For: Newly Diagnosed Acute Myeloid Leukemia (AML) · Untreated AML · AML Arising From Myelodysplastic Syndrome (MDS)United States · Australia · Austria - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies
This study is looking at a new drug, BLU-263, for a rare blood cancer called Advanced Systemic Mastocytosis. It will be tested alone and with another drug, azacitidine, to see how safe it is and how well it works.
For: Advanced Systemic MastocytosisBelgium · Spain · France - Active not recruitingPHASE1, PHASE2
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukaemia (AML) in adults. It's for people who can't have standard, strong chemotherapy. We're testing two combinations of new medicines with an existing drug (azacitidine) to see how safe and effective they are.
For: Leukemia, Myeloid, AcuteUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembrolizumab plus placebo in subjects with previously treated locally advanced or metastatic non-small cell lung cancer
This study is looking for new and better ways to treat advanced lung cancer that has already been treated. It compares a new combination of two drugs – an azacitidine tablet and pembrolizumab – against pembrolizumab with a placebo. The main goal is to see if the new combination can slow down the cancer’s growth.
For: Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
This study is testing a new drug (tamibarotene) alongside a standard treatment (azacitidine) for adults recently diagnosed with a specific type of higher-risk myelodysplastic syndrome (MDS). It aims to see if the new combination helps more patients achieve complete remission.
For: Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic SyndromeAustria · Poland · Czechia - Active not recruitingPHASE1, PHASE2
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
This study looks at a new drug, bexmarilimab, alongside standard treatments for certain blood cancers like leukaemia and MDS. We want to find a safe dose and see how well it works to help patients.
For: Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic SyndromesUnited States · Finland · United Kingdom - Active not recruitingPHASE3
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
This study looks at a new drug, venetoclax, combined with existing treatment, azacitidine, for adults with a type of blood disorder called higher-risk Myelodysplastic Syndrome (MDS). It aims to see if this combination is safe and effective compared to azacitidine alone.
For: Myelodysplastic Syndrome (MDS)United States · Australia · Austria - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - Active not recruitingPHASE1, PHASE2
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
This study is testing a new drug, IMGN632, for adults with a type of blood cancer called Acute Myeloid Leukemia (AML). It's looking at whether IMGN632 is safe and effective when given alone or with other common AML treatments.
For: Acute Myeloid LeukemiaUnited States · France · Germany - RecruitingPHASE2, PHASE3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
This study is testing new ways to treat certain blood cancers, like some types of leukaemia and myelodysplastic syndromes. Researchers are looking at a new drug, ASTX030, sometimes with another drug called venetoclax, to see if it's safe and works better than current treatments.
For: Myelodysplastic Syndromes · Acute Myeloid Leukemia · Myelodysplastic Syndrome/NeoplasmUnited States · Canada · Czechia - RecruitingPHASE3
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
This study looks at two medicines, ivosidenib and azacitidine, for a blood condition called myelodysplastic syndromes (MDS). It's for people with a specific gene change (IDH1 mutation) who haven't had certain treatments before. The aim is to see which medicine works best.
For: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS)United States · Australia · Brazil - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy
This study is looking at a new combination treatment for acute myeloid leukaemia (AML) in people who can't have strong chemotherapy. It combines two drugs, cusatuzumab and azacitidine, to see how well they help improve the patient's condition.
For: Acute Myeloid LeukemiaSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
This study looks at new ways to treat acute myeloid leukaemia (AML) after a stem cell transplant. It combines two medicines, venetoclax and azacitidine, to see if they are safe and help people live longer and healthier lives after their transplant.
For: Acute Myeloid LeukaemiaCzechia · Hungary · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who are Ineligible for Standard Induction Therapy
This study looks at a new drug, tamibarotene, combined with venetoclax and azacitidine, for adults with a specific type of acute myeloid leukaemia (AML) who can't have standard treatment. It aims to see how safe the combination is and if it makes the cancer go into remission.
For: RARA-positive acute myeloid leukemiaFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02)
This study is for people with a type of blood disorder called higher-risk myelodysplastic syndrome (MDS) who haven't had treatment yet. It tests a new drug called ALX148 with an existing medicine, azacitidine, to see if it's safe and helps improve the condition.
For: Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their diseaseSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy, Incorporating Extension Period - Continued Access for Venetoclax. (VIALE-A)
This study looks at a new treatment called venetoclax combined with an existing medicine called azacitidine for people with a type of blood cancer called Acute Myeloid Leukaemia (AML). It aims to see if this combination works better than azacitidine alone for patients who can't have standard strong chemotherapy.
For: Acute Myeloid LeukemiaFinland · Czechia · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This study is testing a new drug, SY-1425, for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers are looking at how well it works, especially for patients with specific genetic markers, and if it's safe when used alone or with other medicines.
For: Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)France - Ongoing, recruitingTherapeutic exploratory (Phase II)
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse (PEMAZA)
This study looks at a new way to treat acute myeloid leukaemia (AML) in adults. It's for people whose AML might be coming back. We're testing a combination of two medicines, pembrolizumab and azacitidine, to see if it can keep the cancer away for longer.
For: Acute myeloid leukemiaGermany - Active not recruitingPHASE1
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
This study looks at a new combination treatment, venetoclax and azacitidine, for people in the UK with a higher-risk type of blood cancer called Myelodysplastic Syndromes (MDS) who haven't had treatment before. It's an early-stage study to find the best dose.
For: Myelodysplastic Syndromes (MDS)United States · Australia · Canada - AuthorisedTherapeutic confirmatory (Phase III)
An international, multicenter, randomized, double-blind, phase 3 pivotal registrational clinical study of APG-2575 (Lisaftoclax) combined with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia (GLORA-3)
This study is testing a new drug, Lisaftoclax, alongside a standard treatment (azacitidine) for older patients with newly diagnosed acute myeloid leukemia (a type of blood cancer). It aims to see if adding Lisaftoclax helps people live longer and improves other aspects of their health.
For: Acute myeloid leukemiaItaly · Spain · Poland